{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:57:47Z","timestamp":1776365867883,"version":"3.51.2"},"reference-count":106,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2010]]},"DOI":"10.2133\/dmpk.25.122","type":"journal-article","created":{"date-parts":[[2010,5,7]],"date-time":"2010-05-07T06:06:43Z","timestamp":1273212403000},"page":"122-133","source":"Crossref","is-referenced-by-count":24,"title":["Prediction of Severe Adverse Drug Reactions Using Pharmacogenetic Biomarkers"],"prefix":"10.2133","volume":"25","author":[{"given":"Masahiro","family":"Tohkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahoko","family":"Kaniwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.25.122_bb0005","series-title":"Text book of adverse drug reactions","first-page":"10","article-title":"Pathogenesis of adverse drug reactions","author":"Rawlins","year":"1977"},{"key":"10.2133\/dmpk.25.122_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch. Dermatol."},{"key":"10.2133\/dmpk.25.122_bb0015","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.2133\/dmpk.25.122_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"10.2133\/dmpk.25.122_bb0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau","year":"1997","journal-title":"J. Dermatol."},{"key":"10.2133\/dmpk.25.122_bb0035","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat. Med."},{"key":"10.2133\/dmpk.25.122_bb0040","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.jid.5700693","article-title":"Soluble Fas ligand: is it a critical mediator of toxic epidermal necrolysis and Stevens-Johnson syndrome?","volume":"127","author":"Murata","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.2133\/dmpk.25.122_bb0045","first-page":"53","article-title":"Drug-induced hepatotoxicity in humans","volume":"11","author":"Halegoua-De Marzio","year":"2008","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.2133\/dmpk.25.122_bb0050","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","author":"Lucena","year":"2009","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.25.122_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf."},{"key":"10.2133\/dmpk.25.122_bb0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0065","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","article-title":"Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis","volume":"292","author":"Psaty","year":"2004","journal-title":"JAMA"},{"key":"10.2133\/dmpk.25.122_bb0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0075","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/pgmj.75.889.680","article-title":"Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins","volume":"75","author":"Edwards","year":"1999","journal-title":"Postgrad. Med. J."},{"key":"10.2133\/dmpk.25.122_bb0080","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0002-9343(91)90216-K","article-title":"Familial occurrence of hypersensitivity to phenytoin","volume":"91","author":"Gennis","year":"1991","journal-title":"Am. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0085","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMe0805136","article-title":"Pharmacogenomics and drug toxicity","volume":"359","author":"Nakamura","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0165-6147(00)01717-X","article-title":"Genetic susceptibility to adverse drug reactions","volume":"22","author":"Pirmohamed","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.2133\/dmpk.25.122_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.2133\/dmpk.25.122_bb0100","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrg1489","article-title":"Gene map of the extended human MHC","volume":"5","author":"Horton","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.2133\/dmpk.25.122_bb0105","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"10.2133\/dmpk.25.122_bb0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0115","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.25.122_bb0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0090-9556(25)07375-1","article-title":"Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s)","volume":"24","author":"Madden","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.122_bb0125","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.2133\/dmpk.25.122_bb0130","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1046\/j.1365-4362.1998.00490.x","article-title":"Erythema multiforme. Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia","volume":"37","author":"Kamaliah","year":"1998","journal-title":"Int. J. Dermatol."},{"key":"10.2133\/dmpk.25.122_bb0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0305-4179(95)00140-9","article-title":"Toxic epidermal necrolysis in a burns centre: a 6-year review","volume":"22","author":"Khoo","year":"1996","journal-title":"Burns"},{"key":"10.2133\/dmpk.25.122_bb0140","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1212\/WNL.49.2.542","article-title":"Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study","volume":"49","author":"Tennis","year":"1997","journal-title":"Neurology"},{"key":"10.2133\/dmpk.25.122_bb0145","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1001\/archinte.1995.00430210033005","article-title":"Anticonvulsant hypersensitivity syndrome","volume":"155","author":"Vittorio","year":"1995","journal-title":"Arch. Intern. Med."},{"key":"10.2133\/dmpk.25.122_bb0150","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1021\/jm00388a004","article-title":"The metabolism of carbamazepine in humans: steric course of the enzymatic hydrolysis of the 10,11-epoxide","volume":"30","author":"Bellucci","year":"1987","journal-title":"J. Med. Chem."},{"key":"10.2133\/dmpk.25.122_bb0155","first-page":"509","article-title":"Protein-reactive metabolites of carbamazepine in mouse liver microsomes","volume":"24","author":"Lillibridge","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.122_bb0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00008571-199406000-00005","article-title":"Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions","volume":"4","author":"Gaedigk","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.25.122_bb0165","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/0006-2952(95)02009-8","article-title":"Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity","volume":"50","author":"Green","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.25.122_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.2133\/dmpk.25.122_bb0175","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B* 1 502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.2133\/dmpk.25.122_bb0180","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.2133\/dmpk.25.122_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome.: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.2133\/dmpk.25.122_bb0190","first-page":"231","article-title":"HLA and drug-induced toxicity","volume":"11","author":"Phillips","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.2133\/dmpk.25.122_bb0195","series-title":"Clin. Transpl","first-page":"139","article-title":"Report of the Japanese Central Bone Marrow Data Center","author":"Tanaka","year":"1996"},{"key":"10.2133\/dmpk.25.122_bb0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/14622416.9.2.207","article-title":"Pharmacogenetic information derived from analysis of HLA alleles","volume":"9","author":"Gatanaga","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.2133\/dmpk.25.122_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","article-title":"Gout and hyperuricemia","volume":"14","author":"Wortmann","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.2133\/dmpk.25.122_bb0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0006-2952(82)90203-9","article-title":"Antileishmanial action of 4-thiopyrazolo (3.4-d) pyrimidine and its ribonucleoside. Biological effects and metabolism","volume":"31","author":"Marr","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.25.122_bb0215","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","article-title":"Human leukocyte antigens and drug hypersensitivity","volume":"7","author":"Chung","year":"2007","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.2133\/dmpk.25.122_bb0220","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.2133\/dmpk.25.122_bb0225","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin. Ther."},{"key":"10.2133\/dmpk.25.122_bb0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0009-2797(02)00059-5","article-title":"The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes","volume":"142","author":"Walsh","year":"2002","journal-title":"Chem. Biol. Interact."},{"key":"10.2133\/dmpk.25.122_bb0235","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.2133\/dmpk.25.122_bb0240","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B * 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.2133\/dmpk.25.122_bb0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","article-title":"Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations","volume":"5","author":"Hughes","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.2133\/dmpk.25.122_bb0250","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.2133\/dmpk.25.122_bb0255","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/QAD.0b013e3280119579","article-title":"Immune responses to abacavir in antigen-presenting cells from hypersensitive patients","volume":"21","author":"Martin","year":"2007","journal-title":"AIDS"},{"key":"10.2133\/dmpk.25.122_bb0260","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0265","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.2133\/dmpk.25.122_bb0270","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-200112070-00008","article-title":"Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile","volume":"1","author":"van der Valk","year":"2001","journal-title":"AIDS"},{"key":"10.2133\/dmpk.25.122_bb0275","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/ACI.0b013e32825ea68a","article-title":"Drug hypersensitivity in HIV","volume":"7","author":"Phillips","year":"2007","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.2133\/dmpk.25.122_bb0280","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.122_bb0285","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157016208783571946","article-title":"Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings","volume":"6","author":"Kiertiburanakul","year":"2008","journal-title":"Curr. HIV Res."},{"key":"10.2133\/dmpk.25.122_bb0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.aids.0000162334.12815.5b","article-title":"The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART","volume":"19","author":"van Leth","year":"2005","journal-title":"AIDS"},{"key":"10.2133\/dmpk.25.122_bb0295","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 *0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"10.2133\/dmpk.25.122_bb0300","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"10.2133\/dmpk.25.122_bb0305","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"10.2133\/dmpk.25.122_bb0310","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.2133\/dmpk.25.122_bb0315","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0320","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157488607780598287","article-title":"Genetic and molecular factors in drug-induced liver injury: a review","volume":"2","author":"Pachkoria","year":"2007","journal-title":"Curr. Drug Saf."},{"key":"10.2133\/dmpk.25.122_bb0325","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/00498250802512830","article-title":"Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes","volume":"39","author":"Laine","year":"2009","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.25.122_bb0330","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/hep.20215","article-title":"HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease","volume":"39","author":"Andrade","year":"2004","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.25.122_bb0335","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0006-2952(91)90282-A","article-title":"N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans","volume":"42","author":"Hickman","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"10.2133\/dmpk.25.122_bb0340","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.25.122_bb0345","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1016\/S0021-9258(19)38219-5","article-title":"Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver","volume":"265","author":"Deguchi","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.2133\/dmpk.25.122_bb0350","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2007.02.009","article-title":"Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury","volume":"47","author":"Huang","year":"2007","journal-title":"J. Hepatol."},{"key":"10.2133\/dmpk.25.122_bb0355","first-page":"2308","article-title":"In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans","volume":"43","author":"Spielberg","year":"1984","journal-title":"Fed. Proc."},{"key":"10.2133\/dmpk.25.122_bb0360","first-page":"733","article-title":"Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility","volume":"6","author":"Rebbeck","year":"1997","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.2133\/dmpk.25.122_bb0365","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0163-7258(90)90054-6","article-title":"Genetic heterogeneity of the human glutathione transferases: a complex of gene families","volume":"48","author":"Board","year":"1990","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.2133\/dmpk.25.122_bb0370","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/carcin\/15.5.1077","article-title":"Ethnic distribution of the glutathione transferase Mu 1\u20131 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility","volume":"1","author":"Lin","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.2133\/dmpk.25.122_bb0375","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.14.11.1083","article-title":"Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM","volume":"14","author":"Iwamoto","year":"1991","journal-title":"Diabetes Care"},{"key":"10.2133\/dmpk.25.122_bb0380","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1021\/jm00122a022","article-title":"Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation","volume":"32","author":"Yoshioka","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.2133\/dmpk.25.122_bb0385","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7326\/0003-4819-130-2-199901190-00021","article-title":"Severe hepatotoxicity associated with troglitazone","volume":"130","author":"Herrine","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.2133\/dmpk.25.122_bb0390","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.2337\/diacare.21.12.2140","article-title":"An autopsy case of troglitazone-induced fulminant hepatitis","volume":"21","author":"Shibuya","year":"1998","journal-title":"Diabetes Care"},{"key":"10.2133\/dmpk.25.122_bb0395","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM199803263381314","article-title":"Hepatic dysfunction associated with troglitazone","volume":"338","author":"Watkins","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.25.122_bb0400","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/dmd.30.2.155","article-title":"Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells","volume":"30","author":"Yamamoto","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.25.122_bb0405","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0009-9236(03)00014-6","article-title":"A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus","volume":"73","author":"Watanabe","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.25.122_bb0410","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenacinduced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"10.2133\/dmpk.25.122_bb0415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.beha.2004.03.002","article-title":"Platelet ADP receptor antagonists: ticlopidine and clopidogrel","volume":"17","author":"Jacobson","year":"2004","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.2133\/dmpk.25.122_bb0420","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hepres.2005.06.009","article-title":"Lessons from ticlopidine-induced liver injury","volume":"33","author":"Takikawa","year":"2005","journal-title":"Hepatol. Res."},{"key":"10.2133\/dmpk.25.122_bb0425","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.hepres.2005.05.009","article-title":"Patient characteristics in ticlopidine hydrochloride-induced liver injury: Case\u2013control study","volume":"33","author":"Mizushima","year":"2005","journal-title":"Hepatol. Res."},{"key":"10.2133\/dmpk.25.122_bb0430","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.tpj.6500442","article-title":"Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case\u2013control study","volume":"8","author":"Hirata","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"10.2133\/dmpk.25.122_bb0435","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/bmj.306.6872.233","article-title":"Risk factors for development of flucloxacillin associated jaundice","volume":"306","author":"Fairley","year":"1993","journal-title":"BMJ"},{"key":"10.2133\/dmpk.25.122_bb0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0168-8278(92)90029-O","article-title":"Liver damage from flucloxacillin, cloxacillin and dicloxacillin","volume":"15","author":"Olsson","year":"1992","journal-title":"J. Hepatol."},{"key":"10.2133\/dmpk.25.122_bb0445","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2125.2005.02370.x","article-title":"Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database","volume":"60","author":"Russmann","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.25.122_bb0450","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.2133\/dmpk.25.122_bb0455","doi-asserted-by":"crossref","first-page":"P21","DOI":"10.1016\/j.clpt.2004.11.081","article-title":"OATP-C(OATP-1B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients","volume":"77","author":"Morimoto","year":"2005","journal-title":"Clin. Phramacol. Ther."},{"key":"10.2133\/dmpk.25.122_bb0460","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2133\/dmpk.19.453","article-title":"A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy","volume":"19","author":"Morimoto","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.25.122_bb0465","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/tpj.2009.3","article-title":"Functional analysis of a mutation in the 105) SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy","volume":"9","author":"Furihata","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"10.2133\/dmpk.25.122_bb0470","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1 *5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.2133\/dmpk.25.122_bb0475","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":"Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.2133\/dmpk.25.122_bb0480","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0091270009341960","article-title":"Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms","volume":"49","author":"Ide","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.25.122_bb0485","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/446975a","article-title":"When good drugs go bad","volume":"446","author":"Giacomini","year":"2007","journal-title":"Nature"},{"key":"10.2133\/dmpk.25.122_bb0490","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1468-1293.2003.00166.x","article-title":"Epidemiological risk factors for hypersensitivity reactions to abacavir","volume":"4","author":"Easterbrook","year":"2003","journal-title":"HIV Med."},{"key":"10.2133\/dmpk.25.122_bb0495","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","article-title":"Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study","volume":"43","author":"Rauch","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.2133\/dmpk.25.122_bb0500","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ACI.0b013e3283079c64","article-title":"The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity","volume":"8","author":"Lavergne","year":"2008","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.2133\/dmpk.25.122_bb0505","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0300-483X(00)00397-8","article-title":"Metabolic activation in drug allergies","volume":"158","author":"Park","year":"2001","journal-title":"Toxicology"},{"key":"10.2133\/dmpk.25.122_bb0510","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8 + T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.2133\/dmpk.25.122_bb0515","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.2133\/dmpk.25.122_bb0520","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2217\/14622416.7.4.633","article-title":"EUDRAGENE: European collaboration to establish a case\u2013control DNA collection for studying the genetic basis of adverse drug reactions","volume":"7","author":"Molokhia","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.2133\/dmpk.25.122_bb0525","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/17425250903018904","article-title":"Drug-induced liver injury: what was new in 2008?","volume":"5","author":"Liss","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.2133\/dmpk.25.122_bb0530","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715300148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715300148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:33:46Z","timestamp":1740072826000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715300148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"alternative-id":["S1347436715300148"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.25.122","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}